The rapidly changing health care landscape in the United States is witnessing a transition from a volume-based to a value-based reimbursement structure. In the process, patient care is also changing.
What steps are biopharmaceutical companies, insurers, and providers taking to create a more value-driven health care system? Is there a role that policymakers can or should play to ensure that this approach improves outcomes and what are the implications for patients?
The Hill will convene policymakers, health industry representatives, and patient advocates for a conversation about the impact of outcomes-based care.
- Liz Fowler, Vice President, Global Health Policy, Johnson & Johnson
- Patrick Geraghty, CEO, GuideWell and Florida Blue
- Pamela Sutton-Wallace, CEO, University of Virginia Medical Center
- Cynthia Zagieboylo, President and CEO, National Multiple Sclerosis Society
Moderated by Kim Dixon, Policy Editor, The Hill
For directions and parking details, click here
